BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 9382172)

  • 1. Pulmonary edema: atypical anaphylactoid reaction to intravenous iron dextran.
    Freter S; Davidman M; Lipman M; Bercovitch D
    Am J Nephrol; 1997; 17(5):477-9. PubMed ID: 9382172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review of available intravenous iron preparations in hemodialysis.
    Palmer K; Cameron K; Battistella M
    CANNT J; 2013; 23(2):51-4; quiz 55-6. PubMed ID: 24069699
    [No Abstract]   [Full Text] [Related]  

  • 3. The safety of intravenous iron dextran (Dexferrum) during hemodialysis in patients with end stage renal disease.
    Hood SA; O'Brien M; Higgins R
    Nephrol Nurs J; 2000 Feb; 27(1):41-2. PubMed ID: 10852689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Parenteral iron therapy: problems and possible solutions].
    Hoigné R; Breymann C; Künzi UP; Brunner F
    Schweiz Med Wochenschr; 1998 Apr; 128(14):528-35. PubMed ID: 9592894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran--a comparison of two products.
    McCarthy JT; Regnier CE; Loebertmann CL; Bergstralh EJ
    Am J Nephrol; 2000; 20(6):455-62. PubMed ID: 11146312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute injury with intravenous iron and concerns regarding long-term safety.
    Bishu K; Agarwal R
    Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S19-23. PubMed ID: 17699372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of total dose iron dextran administration in patients on home renal replacement therapies.
    Sloand JA; Shelly MA; Erenstone AL; Schiff MJ; Talley TE; Dhakal MP
    Perit Dial Int; 1998; 18(5):522-7. PubMed ID: 9848632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients.
    Auerbach M; Winchester J; Wahab A; Richards K; McGinley M; Hall F; Anderson J; Briefel G
    Am J Kidney Dis; 1998 Jan; 31(1):81-6. PubMed ID: 9428456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safe administration of iron dextran to a patient who reacted to the test dose.
    Monaghan MS; Glasco G; St John G; Bradsher RW; Olsen KM
    South Med J; 1994 Oct; 87(10):1010-2. PubMed ID: 7939912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accelerated total dose infusion of low molecular weight iron dextran is safe and efficacious in chronic kidney disease patients.
    Sinha S; Chiu D; Peebles G; Swoboda P; Kolakkat S; Lamerton E; Fenwick S; Bhandari S; Kalra PA
    QJM; 2011 Mar; 104(3):221-30. PubMed ID: 20956457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of total dose infusion of iron dextran in iron deficiency anaemia.
    Reddy CM; Kathula SK; Ali SA; Bekal R; Walsh M
    Int J Clin Pract; 2008 Mar; 62(3):413-5. PubMed ID: 18005041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical update: intravenous iron for anaemia.
    Auerbach M; Ballard H; Glaspy J
    Lancet; 2007 May; 369(9572):1502-1504. PubMed ID: 17482969
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of intravenous iron supplementation in chronic kidney disease: an update.
    Macdougall IC; Geisser P
    Iran J Kidney Dis; 2013 Jan; 7(1):9-22. PubMed ID: 23314137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran.
    Michael B; Coyne DW; Fishbane S; Folkert V; Lynn R; Nissenson AR; Agarwal R; Eschbach JW; Fadem SZ; Trout JR; Strobos J; Warnock DG;
    Kidney Int; 2002 May; 61(5):1830-9. PubMed ID: 11967034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of intravenous iron sucrose versus low-molecular-weight iron dextran in chronic kidney disease.
    Sinha S; Chiu DY; Peebles G; Kolakkat S; Lamerton E; Fenwick S; Kalra PA
    J Ren Care; 2009 Jun; 35(2):67-73. PubMed ID: 19432851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety of intravenous iron dextran in hemodialysis patients.
    Fishbane S; Ungureanu VD; Maesaka JK; Kaupke CJ; Lim V; Wish J
    Am J Kidney Dis; 1996 Oct; 28(4):529-34. PubMed ID: 8840942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fatal anaphylaxis after intravenous iron dextran.
    Zipf RE
    J Forensic Sci; 1975 Apr; 20(2):326-33. PubMed ID: 1123602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of iron deficiency by a bolus intravenous iron dextran in peritoneal dialysis].
    Ficheux M; Cuny P; Lecouf A; Ryckelynck JP; Hurault de Ligny B; Lobbedez T
    Nephrol Ther; 2011 Dec; 7(7):558-61. PubMed ID: 21715234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans.
    Faich G; Strobos J
    Am J Kidney Dis; 1999 Mar; 33(3):464-70. PubMed ID: 10070910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The comparative safety of various intravenous iron preparations in chronic kidney disease patients.
    Anirban G; Kohli HS; Jha V; Gupta KL; Sakhuja V
    Ren Fail; 2008; 30(6):629-38. PubMed ID: 18661414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.